Other News To Note
Kala Pharmaceuticals Inc., of Waltham, Mass., presented preclinical data suggesting that topical delivery of a small-molecule receptor tyrosine kinase inhibitor (RTKi) formulated using its mucosal-penetrating particle (MPP) technology enhanced drug levels in the retina.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST